1
|
Gryzło B, Zaręba P, Malawska K, Mazur G, Rapacz A, Ła̧tka K, Höfner GC, Latacz G, Bajda M, Sałat K, Wanner KT, Malawska B, Kulig K. Novel Functionalized Amino Acids as Inhibitors of GABA Transporters with Analgesic Activity. ACS Chem Neurosci 2021; 12:3073-3100. [PMID: 34347423 PMCID: PMC8397297 DOI: 10.1021/acschemneuro.1c00351] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
![]()
Neuropathic pain
resistance to pharmacotherapy has encouraged researchers
to develop effective therapies for its treatment. γ-Aminobutyric
acid (GABA) transporters 1 and 4 (mGAT1 and mGAT4) have been increasingly
recognized as promising drug targets for neuropathic pain (NP) associated
with imbalances in inhibitory neurotransmission. In this context,
we designed and synthesized new functionalized amino acids as inhibitors
of GABA uptake and assessed their activities toward all four mouse
GAT subtypes (mGAT1–4). According to the obtained results,
compounds 2RS,4RS-39c (pIC50 (mGAT4) = 5.36), 50a (pIC50 (mGAT2) = 5.43), and 56a (with moderate subtype selectivity
that favored mGAT4, pIC50 (mGAT4) = 5.04) were of particular
interest and were therefore evaluated for their cytotoxic and hepatotoxic
effects. In a set of in vivo experiments, both compounds 50a and 56a showed antinociceptive properties
in three rodent models of NP, namely, chemotherapy-induced neuropathic
pain models (the oxaliplatin model and the paclitaxel model) and the
diabetic neuropathic pain model induced by streptozotocin; however
compound 56a demonstrated predominant activity. Since
impaired motor coordination is also observed in neuropathic pain conditions,
we have pointed out that none of the test compounds induced motor
deficits in the rotarod test.
Collapse
Affiliation(s)
- Beata Gryzło
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Paula Zaręba
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Katarzyna Malawska
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Gabriela Mazur
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Anna Rapacz
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Kamil Ła̧tka
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Georg C. Höfner
- Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München Butenandtstraße 5-13, 81377 Munich, Germany
| | - Gniewomir Latacz
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Marek Bajda
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Kinga Sałat
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Klaus T. Wanner
- Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München Butenandtstraße 5-13, 81377 Munich, Germany
| | - Barbara Malawska
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| | - Katarzyna Kulig
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
| |
Collapse
|